Pink SheetPridopidine, Prilenia Therapeutics ’ drug candidate for treating Huntington’s disease, and sebetralstat, KalVista Pharmaceuticals ’ investigational oral, on-demand therapy for hereditary angioedema,
ScripThe positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp
ScripComing off clinical development setbacks, including a failed effort to expand Ingrezza’s label into pediatric Tourette’s syndrome, Neurocrine Biosciences, Inc. reported positive R&D news to its share
ScripVaccinex, Inc. ’s potentially disease-modifying therapy for Huntington’s disease missed its key endpoints in top-line data unveiled 22 September from the Phase II SIGNAL study, but the biotech thinks